Diabetes Learning in Virtual Environments Just in Time for Community Reentry
Part of paid clinical trials in Storrs, Connecticut.
- Sponsor
- Louise Reagan
- Study ID
- NCT05286892
- Status
- Recruiting
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Diabetes LIVE JustICE — OTHERDiabetes LIVE JustICE will be an adaptation of the current Diabetes LIVE persistent multi-user online virtual environment built on the Unreal Engine (Epic Games, Inc., Cary, NC) that allows users to talk to each other in real-time and participate in instructor-led synchronous sessions. Users can access the virtual environment through IOS/Android devices. Instructors can show learning material such as Google Docs and PowerPoint. The LIVE JustICE community will contain a community center, a tranquility center, and a message board. This will be an interactive community where participants will communicate in real-time on their mobile device or, if preferred, using their computer via text or audio chat. Access to LIVE will allow participants to utilize resources and links in the application, leave a message on the message board for the diabetes educators, or engage with other participants. Research team members will add and trial gaming activities to the VE during this feasibility study.
- Enhanced Education — OTHERSee control group description above
Study Details
The proposed study will use a randomized clinical trial design with non-equivalent control group and longitudinal design to evaluate the feasibility, acceptability, and preliminary effects of the Diabetes LIVE JustICE application. The design will incorporate repeated measures at 0, 6, and 12 weeks. Outcome variables will include recruitment assessments, participation, engagement, user experience, and measures proximally related to behavior change - e.g., diabetes knowledge, diabetes-related distress, diabetes self-care, and social support and clinical outcomes -e.g., glycemic control. Focus group interviewing will be conducted to evaluate acceptability among intervention group participants.
Key Dates
- Start date
- Apr 30, 2023
- Status verified
- Jul 2025
- Primary completion
- Nov 15, 2026
- Completion
- Dec 15, 2026
Study Design
- Enrollment
- 128 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- SUPPORTIVE_CARE
Arms
- Active Comparator: ControlParticipants randomized to the control group will receive enhanced pre-release diabetes education with registered or licensed practical nurse-delivered diabetes education about medications and insulin administration supplemented with the literacy tailored diabetes education packets used in the principal investigator's prior research.
- Experimental: InterventionBecause eight avatars plus the educator avatar are allowed in the VE classroom at one time, we will cap enrollment for the feasibility study to allow for CHW and CDE training and the opportunity to work together during LIVE JustICE sessions. The DSMES will consist of six synchronous 1-hour education sessions and an hour support session for participants living in supervised community housing in the experimental group. We will run the six-week series sequentially a total of eleven times over 18 months. LIVE JustICE sessions will be held conveniently for participants, and days/times rotated if needed.
Primary Outcome Measure
Demographics [ Time Frame: baseline ]
Central Contacts
- Lousie Reagan, PhD860-486-0593
- Stephen Walsh, ScD860-486-0544
Locations (2)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| University of Connecticut | Storrs | Connecticut | 06269 | Louise A Reagan, PhD (PRINCIPAL_INVESTIGATOR) Stephen J Walsh, PhD (SUB_INVESTIGATOR) |
| University of Connecticut | Storrs Mansfield | Connecticut | 06269-0001 |
Find similar trials in Storrs, CT
Related Studies
- TrialNet Pathway to Prevention of T1DRecruiting · University of South Florida · Orange, California
- Regulation of Brain Glucose Metabolism in Type 1 DiabetesEARLY_PHASE1 · Recruiting · Yale University · New Haven, Connecticut
- Reversibility of Brain Glucose Transport in Type 2 Diabetes Mellitus (T2DM)Recruiting · Yale University · New Haven, Connecticut
- EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular DiseasePHASE3 · Recruiting · Boehringer Ingelheim · Anniston, Alabama